Please login to the form below
Amgen and Takeda lung drug fails trial
Amgen and Takeda have revealed that its lung cancer drug motesanib has failed to meet its endpoint in a phase III trial
Amgen and Takeda have revealed that its lung cancer drug motesanib has failed to meet its endpoint in a phase III trial.
The drug failed to demonstrate an improvement in overall survival rate when combined with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer.
In this trial, as in earlier trials of motesanib, the patients who received the drug were also more likely to experience serious adverse events more frequently than those who were given a placebo. Among the adverse events reported were hypertension and bleeding disorders.
Roger M Perlmutter, executive vice president of research and development at Amgen, said: "We are disappointed with the results from this trial, but look forward to further analysis of the data which may ultimately help inform future research in this area."
No decision has been made about continuing development.
Share
Related Hub content
Your search did not contain any words. Please try again.
Featured jobs
- Senior Brand Manager - Harlow
- Competitive
- Sales Manager - Media Publishing – Cheshire
- 25,000 to 35,000 per annum
- UK Marketing Director
- 80,000 to 100,000 per annum
- Group Account Director –Healthcare Advertising
- Neg
Subscribe to our email news alerts
- Global biosimilars market to reach $2.45bn in 2013
- Bringing trial data out of the shadows
- Novartis gets FDA green light for new Ilaris indication
- Brazil eHealth pilot improves healthcare access for city poor
- Amgen and Novartis partner with biotech venture capital firm
- GSK wins US approval for Seretide successor Breo Ellipta
- Spectrum Thea signs sales force agreement in UK
- Adelphi Communications re-launches global network
- VCCP Health wins Mundipharma’s new product launch business
- England to launch 15 networks for NHS to work with academia
- A look back at Sanofi's merger with Synthélabo
- New chief information officer at Bayer Healthcare
PMHub
Add my companyApotheCom
ApotheCom is the medical communications division of Huntsworth Health, which is a global family of best-in-class agencies that provide a ...
Latest intelligence
- Clinical trial regulation in Mexico
- Regulatory improvements make Mexico an appealing destination for clinical trials outsourcing...
- How can pharma deliver returns on increased digital investment?
- Independent online professional networks work best as part of a multi-channel campaign ...
- The impact of Hollande's healthcare reforms in France
- A tougher environment for pharma, with market access and regulatory challenges...
Quick links
